Psychedelic medicine is having its scientific moment. Most coverage cannot tell breakthrough from press release. Every Tuesday, you get the difference, in plain language, with the citations to back it up.
In 2026, more than 1,800 articles will be published about psychedelic medicine. Most will be press releases dressed as journalism. A small fraction will move the science forward. We read everything. We write only about what matters.
Every issue follows the same arc: observation, evidence, takeaway. The structure is what makes it readable in five minutes and useful for the rest of the week.
PubMed, ClinicalTrials.gov, FDA filings, EMA notices, conference proceedings, and direct conversations with researchers. So you do not have to.
Press releases get cross-checked against trial data. Hot takes get checked against the underlying paper. Hype gets named as such.
500 to 1,000 words. Charts where they help. Citations always. Written so a curious patient and a working researcher both leave with something useful.
The psychedelic medicine space moves fast and gets reported badly. The Rose Hill Review exists for the readers who cannot afford either problem.
Veterans, those exploring options for treatment-resistant depression, PTSD, stroke recovery, plus the people supporting them. Get clarity on what is available, what is coming, and what is still hype.
LPs, family offices, and operators trying to separate credible early-stage opportunities from PR-driven promotion. We name names, cite sources, and flag what is actually moving.
Neuroscientists, psychiatrists, and trial coordinators who want consolidated weekly updates on protocols, outcomes, and regulatory shifts — drawn from primary sources, not secondhand summaries.
Health journalists, policy thinkers, and the genuinely curious. Accessible explainers grounded in primary research. No woo. No moral panic. Just the work.
Researchers, investors, and patients sharing what the Rose Hill Review does for their week.
The only psychedelic newsletter I forward to my entire research team. They do the work of reading the actual papers so we do not have to argue about second-hand summaries.
I run a fund focused on this space. The Rose Hill Review is the first thing I read Tuesday morning. It is the only one I trust to flag a press release dressed up as a breakthrough.
As a veteran exploring trial options, this newsletter cut through more confusion in three issues than six months of forums. Honest, careful, never selling me anything.
Domenic is the co-founder and Chief Operating Officer of Rose Hill Health Holdings, with 11+ years as a senior executive in operationally complex, highly regulated industries. His path into alternative medicine started in 2010 with a seed investment into Evolab, a Denver-based vertically integrated cannabis company, where he served as COO from 2013 to 2018 through the acquisition by Harvest Health and Recreation (HARV: CSE). He went on to lead manufacturing operations at Supreme Cannabis (CSE: FIRE), supported the BLISSCO acquisition, and has worked with national brands including KKE, Monogram, Native Sun, Terps, and Tilt.
The Rose Hill Review was built because credible science kept getting crowded out by hot takes, and credible companies kept getting conflated with hype factories. Each issue is built from primary sources: peer-reviewed papers, regulatory filings, trial registries, and direct conversations with the researchers and clinicians shaping the field. The goal is not to be the loudest voice in psychedelic medicine. It is to be the one you trust when the next headline drops.
